The Healthcare Benefits of fFN Testing

  • Timely and appropriate interventions, such as antenatal steroids and magnesium sulfate.
  • Avoidance of unnecessary hospitalizations. One study showed that the average length of stay for patients with symptoms of preterm labor was reduced from 5.2 days to just 0.6 days after fFN testing was adopted.3
  • Effective transfer of patients at high risk of imminent preterm birth to a hospital with an appropriate NICU.

Interpreting Results

Negative Result2

  • Approximately 80% of patients will get a negative result.
  • A negative result means that patients have a less than 1% chance of giving birth in the next two weeks.
  • A negative result can help avoid unnecessary drug treatments, bed rest and hospitalizations. This knowledge can also provide peace of mind, freeing patients to continue with current activities without unnecessarily cancelling or rescheduling plans.
  • The Rapid fFN test can be repeated as often as every 2 weeks to monitor ongoing risk.

Positive Result2

  • Approximately 20% of patients will get a positive result
  • A positive result means the body is “leaking” fetal fibronectin, a sign that the patient may be preparing to give birth.
  • A positive result does not necessarily mean the patient will deliver soon, but it will alert the doctor to the fact that they are at higher risk for preterm labor.
  • The Rapid fFN test can be repeated as often as every 2 weeks to monitor ongoing risk.


Fetal Fibronectin: A powerful predictor of preterm birth

fFN is an adhesive glycoprotein found at the maternal-fetal interface which functions like a glue to bind the baby to the uterus during fetal development.fFN is generally absent in vaginal secretions during weeks 16 to 35 of gestation, so if fetal fibronectin is detectable in vaginal discharge during pregnancy weeks 22-35, it means that the protein is “leaking.” This can alert healthcare providers that the patient is at risk of preterm birth.


Curabitur accumsan auctor ipsum, eget aliquam tellus dignissim id. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Sed vehicula scelerisque lacus id ultrices. Nullam vestibulum pharetra orci vel venenatis. Proin in pulvinar lorem, sed tempor felis. Cras tincidunt non felis imperdiet lobortis. Nulla nec nisl tempor, tincidunt lectus quis, tincidunt leo. Quisque laoreet ac velit fringilla tempor. Nullam a sollicitudin tellus. Curabitur et nulla quis diam porttitor tempor sed eu magna. Sed magna magna, fringilla vel luctus at, eleifend vitae risus. Fusce maximus pellentesque risus at ornare. Ut fermentum semper elit.

More Products

Panther Fusion® Open Access™

Laboratory Developed Tests (LDTs) are an essential part of diagnostics. Patients with certain medical conditions depend on these in-house developed tests when other options are not available. Save time and increase efficiency by consolidating your LDTs and IVD assays on the fully automated, sample-to-result, Panther Fusion system using the Open Access™ functionality.

Aptima® Vaginal Health

The Aptima vaginitis panel from Hologic consists of molecular nucleic acid amplification tests (NAAT) to aid in the detection of vaginosis and vaginitis. Our assays detect the three most common causes of infectious vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis.

Aptima® HIV-1 Quant Dx Assay

Dual-claim assay to confirm HIV-1 infection and measure viral load.

Aptima® Herpes Simplex 1 & 2 assay

Globally, over 4.1 billion people are infected with HSV-1 and HSV-2 and the signs and symptoms can overlap.1 It is only through laboratory tests that these subtypes can be differentiated, which is important for managing herpes infections and identifying the risk of transmission to neonates and among sex partners.2,3